Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest update is out from GNI Group ( (JP:2160) ).
GNI Group Ltd.’s subsidiary, Gyre Therapeutics, has successfully completed a Phase 3 clinical trial in China for their liver fibrosis treatment drug, F351. The trial’s success, demonstrating significant fibrosis regression, positions the company favorably in the Chinese market for chronic hepatitis B-related liver fibrosis treatments.
The most recent analyst rating on (JP:2160) stock is a Buy with a Yen3700.00 price target. To see the full list of analyst forecasts on GNI Group stock, see the JP:2160 Stock Forecast page.
More about GNI Group
GNI Group Ltd. operates in the pharmaceutical industry, focusing on developing innovative treatments for various medical conditions. Its primary products and services include therapeutics for liver fibrosis and other chronic diseases, with a significant market focus in China.
Average Trading Volume: 2,353,867
Technical Sentiment Signal: Hold
Current Market Cap: Yen124.8B
See more insights into 2160 stock on TipRanks’ Stock Analysis page.